Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.87 |
| ▸ | LMNA | P02545 | 3/20 | 0.87 |
| ▸ | HPGD | P15428 | 2/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiophanate Methyl SCHEMBL29422247 | 0.93 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDALOX15HSD17B10 | |
| Thiophanate Methyl SCHEMBL41622 | 0.93 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDALOX15HSD17B10 | |
| Thiophanate Methyl SCHEMBL16537027 | 0.91 | ALDH1A1 (0.96) | ALDH1A1LMNAHPGDALOX15HSD17B10 | |
| Thiophanate Methyl SCHEMBL28315984 | 0.91 | ALDH1A1 (0.96) | ALDH1A1LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL11677384 | 0.90 | ALDH1A1 (0.81) | ALDH1A1LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL11677871 | 0.90 | ALDH1A1 (0.93) | ALDH1A1LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL9425843 | 0.89 | ALDH1A1 (0.67) | ALDH1A1LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL11676773 | 0.88 | ALDH1A1 (0.90) | ALDH1A1LMNAHPGDALOX15HSD17B10 | |
| SCHEMBL23002880 | 0.88 | ALDH1A1 (0.65) | ALDH1A1LMNAHPGDALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL2672460 | 0.88 | ALDH1A1 (0.65) | ALDH1A1LMNAHPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092418-A1 | METHODS OF GENETICALLY ALTERING A PLANT NIN-GENE TO BE RESPONSIVE TO AUXIN | NIAB (GB) | 2025-03-20 | — | — | US | disclosed |
| WO-2025045890-A1 | METHODS OF GENETICALLY ALTERING A PLANT NIN-GENE TO BE RESPONSIVE TO AUXIN | NIAB (GB) | 2025-03-06 | — | — | WO | disclosed |
| US-20240271134-A1 | OLIGONUCLEOTIDES AND COMPOSITIONS THEREOF FOR NEUROMUSCULAR DISORDERS | MIRECULE INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240093287-A1 | METHODS AND COMPOSITIONS FOR REDUCING INDEX HOPPING | GINKGO BIOWORKS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20230391817-A1 | 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | DENDROGENIX (BE) | 2023-12-07 | — | — | US | disclosed |
| EP-4236963-A1 | 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | Dendrogenix (BE) | 2023-09-06 | — | — | EP | disclosed |
| CN-116615202-A | 5 alpha-hydroxy-6 beta- [2- (1H-imidazol-4-yl) ethylamino ] -cholestan-3 beta-ol analogues for the treatment of cancer and pharmaceutical compositions comprising the same | 登德罗杰尼克斯公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2022090427-A1 | 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | DENDROGENIX (BE) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022026887-A1 | METHODS AND COMPOSITIONS FOR REDUCING INDEX HOPPING | GINKGO BIOWORKS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391817-A1 | 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | CYP46A1, CYP27A1, DHCR7 | ALDH1A1 828/4885LMNA 2951/4885HPGD 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.